J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide

Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.

Cancer cell division of two prostate cancer cells in the final stage of cell division (cytokinesis) cytoplasm divides. the cells are joined by several thin cytoplasmic bridges. They to form tumours

Janssen Biotech Inc. hopes it will be first to market with a drug for non-metastatic castration-resistant prostate cancer (CRPC) with the submission of its next-generation androgen receptor inhibitor apalutamide, based on a Phase III study providing data on metastasis-free survival.

Apalutamide will be positioned in tandem with Janssen’s blockbuster prostate cancer therapy Zytiga (abiraterone acetate). "Prostate cancer is an area...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category